Regulatory guidance plays a critical role in clinical trial development, but it cannot anticipate every question that may emerge during the development of a program. When guidance is absent, outdated or inconsistent across authorities, sponsors have legitimate room to exercise judgment. However, that flexibility should be approached as conditional rather than permissive. Flexibility in a program’s design does not change the level of scrutiny that regulators will apply to the evidence sponsors provide.

This distinction requires sponsors to look beyond whether a program simply satisfies written guidance and consider the regulatory decision the evidence will ultimately need to support. While a study can follow available recommendations to the letter, it may fall short on generating the essential evidence needed to resolve the questions regulators will pose during review. By considering the eventual regulatory decision throughout development, sponsors can ensure that the evidence collected can support a clear conclusion about a therapy. 

Bringing a novel drug or therapy to market can take up to 12 years, on average. At the same time, pressure to accelerate this process continues to grow. According to Deloitte’s 2026 Life Sciences Outlook, 41% of surveyed biopharma executives responded that R&D productivity or product-development efficiency are a priority for managing costs in 2026. This long process means that clinical trial design decisions are often made years before regulators evaluate the complete evidence package. 

Sponsors must therefore consider the eventual regulatory decision from the outset and think ahead, defining what the study ultimately needs to demonstrate for the intended treatment population.

Source link